ArticleJournal of Cancer2021
ApoM is an important potential protective factor in the pathogenesis of primary liver cancer.
Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- APOM Modulates the Glycolysis Process in Liver Cancer Cells by Controlling the Expression and Activity of HK2 via the Notch Pathway.Biochemical genetics · 2026Article
- Exploring the evolving role of apolipoproteins in oncology: global trends and emerging frontiers.Journal of cancer research and clinical oncology · 2025Article
- Novel nomograms based on microvascular invasion grade for early-stage hepatocellular carcinoma after curative hepatectomy.Scientific reports · 2024Article
- The role of novel adipokines in hepatocellular carcinoma progression: a mini review.American journal of cancer research · 2024Review
- Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.Breast cancer research and treatment · 2023Article
- ApoM regulates PFKL through the transcription factor SREBF1 to inhibit the proliferation, migration and metastasis of liver cancer cells.Oncology letters · 2022Article
- Review
- The integrated landscape of fatty acid metabolism subtypes reveals with prognostic and therapeutic relevance in pancreatic cancer.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Article
- Apolipoproteins: New players in cancers.Frontiers in pharmacology · 2022Review
- Effectiveness and Safety of the Traditional Chinese Medicine Treatment (Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Persistence of Lipoproteins and Cholesterol Alterations after Sepsis: Implication for Atherosclerosis Progression.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, abnormal liver lipid metabolism has emerged as one of the important pathogenesis pathways of primary liver cancer. It is highly important to identify the mechanisms to explore potential prevention and treatment targets. Apolipoprotein M is specifically expressed in the liver and participates in liver lipid metabolism, but the evidence that ApoM affects primary liver cancer is insufficient. The Cancer Genome Atlas (TCGA) database and clinical case analysis, as well as animal level and cell level analysis suggest that the expression level of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.